Results 341 to 350 of about 14,611,928 (419)

A Placebo-Controlled Double-Blind Study on the Effect of Nutraceuticals (Chondroitin Sulfate and Mussel Extract) in Dogs with Joint Diseases as Perceived by Their Owners

, 2002
Britta Dobenecker, Yvonne Beetz, Ellen Kienzle   +2 more
openalex   +1 more source

GDF15 Analogues Acting as GFRAL Ligands

ChemMedChem, EarlyView.
Considering the great importance of the GDF15/GRAL/RET signalling pathway, this review focuses on GDF15‐derived analogues able to act either as GFRAL agonists or antagonists, investigating their possible pharmacological applications in the treatment of GDF15‐related conditions, such as obesity and diabetes (agonist), or cancer‐induced nausea and ...
Andrea Di Santo, Livio Tarchi, Gianluca Villa, Giovanni Castellini, Valdo Ricca, Roberta Squecco, Anna Maria Papini, Feliciana Real‐Fernandez, Paolo Rovero   +8 more
wiley   +1 more source

Deciphering the transcriptomic landscape of early HR+/HER2− breast cancer in very young women

Cancer Communications, EarlyView.
Iris Garrido‐Cano, Marta Tapia, Juan Carbonell, Carlos Peña, Sandra Torres‐Ruiz, Anna Ágreda‐Roca, Ana Lameirinhas, Cristina Tebar, Octavio Burgués, Cristina Hernando, Ana Lluch, Fara Brasó‐Maristany, Aleix Prat, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo   +15 more
wiley   +1 more source

The Effect of Midazolam on Stress Levels During Simulated Emergency Medical Service Transport: A Placebo-Controlled, Dose-Response Study

, 2002
Volker Dörges, Volker Wenzel, Susanne Dix, Alexander Kühl, Thomas Schumann, Michael Hüppe, H. Iven, Klaus Gerlach   +7 more
openalex   +1 more source

The effect of desloratadine on eosinophil/basophil progenitors and other inflammatory markers in seasonal allergic rhinitis: A placebo-controlled randomized study

, 2002
Michael M Cyr, Adrian J. Baatjes, Lisa Hayes, Lynn Crawford, Judah A. Denburg   +4 more
openalex   +1 more source

Target‐Mediated Modeling of Alirocumab in Adolescents and Children ≥8 to <12 Years of Age Using Phase II and III Data

Clinical Pharmacology in Drug Development, EarlyView.
Abstract A population pharmacokinetic (PK) covariate analysis was conducted utilizing data from adolescents and children ≥8 to <12 years of age with heterozygous familial hypercholesterolemia. One phase II and 1 phase III study were analyzed (121 patients on active treatment).
Pavel Kovalenko, Lutz Harnisch, Jeanne Mendell, Yuhuan Wang, John D. Davis, Albert Thomas DiCioccio   +5 more
wiley   +1 more source

A Phase 1C, Open Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DM199 Administered Intravenously with a Polyvinyl Chloride Bag in Adult Healthy Subjects and Adults Recently Taking Angiotensin‐Converting Enzyme Inhibitors

Clinical Pharmacology in Drug Development, EarlyView.
Abstract This small phase 1C, open‐label, single ascending dose study evaluated the safety, tolerability, and pharmacokinetics (PKs) of DM199, a recombinant form of human tissue kallikrein‐1 (KLK1). A small sample size of both healthy subjects and hypertensive adults recently taking angiotensin‐converting enzyme inhibitors was studied. KLK1 has a known
Michael Giuffre, Annette D. Lista, Nick Paulson, Lorianne Masuoka   +3 more
wiley   +1 more source

Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial

Clinical Pharmacology &Therapeutics, EarlyView.
Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders, for which concomitant treatment with selective serotonin reuptake inhibitors (SSRIs) is prevalent.
Anna M. Becker, Mélusine Humbert‐Droz, Lorenz Mueller, Alen Jelušić, Avram Tolev, Isabelle Straumann, Isidora Avedisian, Livio Erne, Jan Thomann, Dino Luethi, Edna Grünblatt, Henriette Meyer zu Schwabedissen, Matthias E. Liechti   +12 more
wiley   +1 more source

A Benchmark, Expand, and Calibration (BenchExCal) Trial Emulation Approach for Using Real‐World Evidence to Support Indication Expansions: Design and Process for a Planned Empirical Evaluation

Clinical Pharmacology &Therapeutics, EarlyView.
Real‐world evidence involving healthcare database studies is well established for making causal inferences in post‐market drug safety studies and methods, data, and research infrastructure for evaluating effectiveness have advanced in recent years. The rapidly expanding field of etiologic research using insurance claims and electronic health records ...
Shirley V. Wang, Massimiliano Russo, Robert J. Glynn, Marie C. Bradley, Jiwei He, John Concato, Sebastian Schneeweiss   +6 more
wiley   +1 more source

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost

Clinical Pharmacology &Therapeutics, EarlyView.
Model‐informed drug development (MIDD) integrates data to quantify benefit/risk informing objective drug discovery and development decisions. An additional critical benefit of MIDD is postulated to be improvement in trial and program efficiencies. While the application of MIDD has grown, there have been no clear examples across programs to demonstrate ...
Vaishali Sahasrabudhe, Timothy Nicholas, Gianluca Nucci, Cynthia J Musante, Brian Corrigan   +4 more
wiley   +1 more source